Food intake is a form of behavior that is subject to conscious control. In practice, many obese and weight-gaining individuals claim that their eating is out of control. Rapid progress is being made in understanding the brain processing and related psychology of the sensory properties of food, and how the satiety (fullness) signals produced during and after eating regulate appetite. With over 3 years of working closely with our customers, HDB metabolic disease group engage in the studies of a wide range of obesity targets, such as GHSR 1a antagonism and CB1 receptor antagonism.
Fig. 5 Validation study of acute food intake screening with Ghrelin. A. Dose response of Ghrelin on acute food
intake screening model (mouse); B. Dose response of Ghrelin on growth hormone release model (mouse).
Fig. 6 Acute food intake screening model by sugical manipulation. Stimulating effect on food intake of Ghrelin was
evaluated in C57BL/6 mouse following ICV microinjection.
The Latest Generation of Auto Patch Clamp Platform Launched at HDB
----------------------
WuXi Biology/HD Biosciences Presented at Webinar of "New Technologies for Target Discovery and Validation"
The Latest Generation of Auto Patch Clamp Platform Launched at HDB
We are excited to announce the installation and operation of SyncroPatch 384, the latest generation of automated patch clamp (APC) system which can be implemented into all phases of drug discovery.
•
WuXi Biology/HD Biosciences Presented at webinar of "New Technologies for Target Discovery and Validation"
Novel target discovery and validation are the most crucial steps and prerequisites for successful drug development.
•
HD Biosciences Merges with WuXi AppTec
HD Biosciences Co., Ltd. (HDB), a leading biology-focused preclinical drug discovery contract research organization (CRO), today announces its merge with WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform.